Author

Ryan R. Davis

University of California Davis Medical CenterORCID 0000-0001-7439-6683Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

Ashish KumariD· 1 shared Clifford G. TepperiD· 1 shared Edmond F. O’DonnelliD· 1 shared Janai R. CarriD· 1 shared Jessica BergonioiD· 1 shared Jonna Magdallene Espera· 1 shared Kang-Hsin Wang· 1 shared Ken-ichi Nakajima· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Ashish KumarORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologyMolecular Therapy OncologyPeer-reviewedSep 5, 2025

Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases

Tomoki Inagaki, Jonna Magdallene Espera, Kang-Hsin Wang…·Yoshihiro Izumiya

This paper develops a gene therapy vector targeting KSHV-infected cells using AAV8-TR2-OriP-TK, which, when combined with ganciclovir, effectively eradicates KSHV-associated cancers in xenograft models.

7 citations

humanexperimental assay

𝕏 PostBluesky

Cancer Biologynpj Precision OncologyPeer-reviewedJan 9, 2025

Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic Target

Edmond F. O’Donnell, Maria Muñoz, Ryan R. Davis…·Janai R. Carr

The paper identifies EZH2 as a therapeutic target in sarcoma stem cells (STS-CSCs) across subtypes, showing that targeting EZH2 reduces CSC populations and restores chemosensitivity in resistant cell lines.

10 citations

humanbulk RNA-seq

𝕏 PostBluesky